Applications Published 20 March 2002

Published: 1-Oct-2002

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).



  • Stable benzimidazole formulation
    Lahav, Raffael 1187599*

  • Method for enhancing stable cellular creatine concentration
    Fortress Systems 1187600*

  • Novel preparation and administration form comprising an acid-labile active compound
    Byk Gulden Lomberg Chemische Fabrik 1187601*

  • Injectable sustained release pharmaceutical compsn and processes for preparing same
    Peptron 1187602*

  • Combination therapy for effecting weight loss and treating obesity
    Najarian, Thomas 1187603*

  • Compounds and methods for the treatment of post-traumatic stress disorder
    Berlant, Jeffrey 1187604*

  • Non-malignant disease treatment with RAS antagonists
    Thyreos Corp; Ramot University Authority for Applied Research and Industrial Development 1187605*

  • Pharmaceutical compsn containing sibutramine and orlistat
    Knoll 1187606*

  • Indole compounds
    SmithKline Beecham 1187607*

  • Indole compounds
    SmithKline Beecham 1187608*

  • Treatment and analysis of proliferative disorders
    The General Hospital Corp 1187609*

  • Use of ion channel modulating agents
    Neurosearch 1187610*

  • Ophthalmic histamine compsns and uses thereof
    Maxim Pharmaceuticals 1187611*

  • Use of riluzole for the treatment of multiple sclerosis
    Verneniging voor Christelijk Wetenschappelik Onderwijs 1187612*

  • Amide-substituted imidazoquinolines
    3M Innovative Properties 1187613*

  • Substituted piperadines as melanocortin-4 receptor agonists
    Merck 1187614*

  • Immunosuppressive effects of pteridine derivatives
    KU Leuven Research & Development 1187615*

  • Thrombin inhibitors
    Merck 1187616*

  • Topical ophthalmic mast cell stabilisers for treating allergic eye diseases
    Alcon Laboratories 1187617*

  • Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
    The General Hospital Corp 1187618*

  • Anti-tumour agents containing boroproline compounds
    Point Therapeutics 1187619*

  • Antisense modulation of B7 protein expression
    Isis Pharmaceuticals 1187620*

  • Novel pharmaceutical combination based on erythromycin and a carboxylic acid having 7 to 13 carbon atoms
    Societe B F B 1187621*

  • Conformationally constrained backbone cyclised interleukin-6 antagonists
    Peptor 1187624*

  • Structure-based design of compounds that inhibit detrimental cytotoxic T lymphocyte responses
    Philadelphia Health and Education Corp 1187625*

  • Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischaemic or reperfused brain
    Bionebraska 1187628*

  • Adjuvant compsns comprising saponin and a immunostimulatory oligonucleotide
    SmithKline Beecham 1187629*

  • Rapid immunoassay to detect antibodies in saliva to diease-related microrganisms antigens
    The Government of the United States of America as represented by the Secretary of the Navy 1187630*

  • Prevention of type-1 diabetes and other non-polio enterovirus diseases
    Hyoety, Heikki; Knip, Mikael 1187631*

  • Treatment with anti-ERBB2 antibodies
    Genentech 1187632*

  • Anaesthetic formulation comprising an NMDA-antagonist and an alpha-2 adrenergic agonist
    Imperial College of Science, Technology and Medicine 1187635*

  • Injectable hyaluronate-sulphated polysaccharide conjugates
    Orquest 1187636*

  • Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
    Deirx Pharmaceutical Corp 1187639*

  • You may also like